Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2, 2-STAGE, 2-COHORT STUDY OF TALAZOPARIB (BMN 673) ADMINISTERED TO GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER

NCT02034916 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02034916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02034916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2, 2-STAGE, 2-COHORT STUDY OF TALAZOPARIB (BMN 673) ADMINISTERED TO GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
December 13, 2013
Completion date
October 31, 2018
Enrollment
84 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

brca 1 gene mutation, brca 2 gene mutation, breast neoplasms